ライフサイエンスコーパス: there remain

1 However, there remain a large number of TFs ( approximately 800)

2 Yet there remain a number of challenges, including diverse p

3 losis and active tuberculosis are available, there remain a number of clinical areas with limited gui

4 However, there remain a number of technical challenges to be solv

5 ienced rapid growth over the last few years, there remain a relatively small number of material class

6 ssfully in murine embryonic stem (ES) cells, there remain a set of nearly two thousand genes that hav

7 However, there remain a subset of patients who have continued sev

8 However, in 2009-2011, there remained a higher rate of AIDS-related mortality (

9 ions used automatic tube current modulation, there remained a large variation of practice, on the ord

10 tatin therapy candidates at 55 years of age, there remained a significant association between cumulat

11 those seen in non-genetic primary cases but there remained a significant beneficial effect.

12 When death alone was evaluated, there remained a significant increase in the event rate

13 gitation from baseline to post intervention, there remained a statistically significant difference (p

14 However, there remained a wide variation in practice, sometimes b

15 I propose that there remains a central role for the item (or its equiva

16 ulates avoid energy infrastructure; however, there remains a common perception that ungulates habitua

17 cultural production throughout the world, so there remains a compelling need to develop new vector an

18 g genomic instability has been acknowledged, there remains a critical gap in the direct evidence of t

19 iterature on comorbidity risks in psoriasis, there remains a critical knowledge gap on the degree to

20 Thus, there remains a critical need for HH inhibitors with dif

21 There remains a critical need for randomized clinical tr

22 quantification have decreased considerably, there remains a critical need for researchers to optimiz

23 Consequently, there remains a critical need for strategies to increase

24 ecies and environmental conditions; as such, there remains a critical need to focus research efforts

25 technological advances over the past decade, there remains a critical need to translate the fruits of

26 Despite this fact, there remains a dearth of available software tools desig

27 However, there remains a dearth of evidence guiding treatment in

28 espite the large amount of accumulated data, there remains a dearth of understanding of FGF21 physiol

29 have been developed to improve performance, there remains a gap between promising laboratory results

30 ge through the AQP pore are established, but there remains a gap in our knowledge of how water transp

31 However, there remains a glaring mismatch between where studies o

32 Consequently, there remains a great need for reliable serum markers fo

33 alties, traditionally male-dominated fields, there remains a gross under-representation of women in t

34 s event could have been anticipated and that there remains a high chance of exceeding observed record

35 anticipated, and that in the current climate there remains a high chance of exceeding the observed re

36 , or when duodenal biopsies are negative and there remains a high index of suspicion.

37 Third, there remains a lack of agreement or standardization as

38 gnosis and high relapse after treatment, but there remains a lack of biomarkers and effective targete

39 Yet there remains a lack of clarity about how to optimize sc

40 Despite decades of research, there remains a lack of consensus regarding certain aspe

41 There remains a lack of evidence concerning both pharmac

42 However, there remains a lack of good evidence for the efficacy o

43 ew vessels from the preexisting vasculature, there remains a lack of insight of the nuclear transcrip

44 However, there remains a lack of practical methods to detect and

45 However, there remains a lack of statistically sound frameworks t

46 Furthermore, there remains a lack of targeted therapies that result i

47 e of death in pediatric neuroblastoma, where there remains a lack of therapies to target this stage o

48 However, there remains a lack of understanding regarding ripple d

49 There remains a large discrepancy between the known gene

50 There remains a limited role for angioplasty because thi

51 However, there remains a major gap in our understanding of the in

52 There remains a major unmet need for successful manageme

53 Despite advances, there remains a need for a method that combines the simp

54 are ubiquitous groundwater contaminants, yet there remains a need for a method to efficiently monitor

55 s (CNVs) from next-generation sequence data, there remains a need for a system that is computationall

56 There remains a need for additional high-quality longitu

57 ing cause of death in developed nations, and there remains a need for cardiac therapeutic systems tha

58 rtially address the problem of interferents, there remains a need for developing direct observational

59 ols are inconvenient to use in practice, and there remains a need for easy-to-use cross-platform tool

60 ment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progre

61 There remains a need for heightened levels of concern re

62 ic segmentation techniques for mitochondria, there remains a need for more accurate and robust techni

63 tand and treat acute myeloid leukemia (AML), there remains a need for more comprehensive therapies to

64 Thus, there remains a need for novel therapeutics that can tar

65 There remains a need for novel therapies targeting HBV r

66 There remains a need for such compounds with the balance

67 ed structure in data to generate hypotheses, there remains a need for testing hypotheses and interpre

68 toward the development of new IR probes, but there remains a need for those that can extend the exper

69 he emergence of site-specific endonucleases, there remains a need for tools capable of specifically d

70 However, there remains a need to anticipate supply given the rapi

71 aneous mastocytosis (CM) have been proposed, there remains a need to better define subforms of cutane

72 key contributors to metastatic disease, and there remains a need to better understand and target the

73 er still carries a poor prognosis, and thus, there remains a need to elucidate the molecular mechanis

74 and mortality associated with this disease, there remains a need to elucidate the molecular mechanis

75 There remains a need to identify further markers of FU t

76 There remains a need to identify novel pro-resolution dr

77 Thus, there remains a need to identify predictive biomarkers t

78 nd acquired resistance to endocrine therapy, there remains a need to identify which ERalpha-positive

79 rapeutic potential in severe infections, but there remains a need to substantiate clinical benefit.

80 n tissue development and cell proliferation, there remains a paucity of approaches to investigate the

81 als involved in the formation of the kidney, there remains a paucity of functional studies.

82 However there remains a paucity of information about overall cap

83 There remains a paucity of information on the status of

84 There remains a paucity of information regarding mechani

85 ing' interventions for people with psychosis there remains a paucity of research.

86 There remains a possibility of a small reduction in the

87 There remains a possibility of structural artefacts aris

88 s well described from postmortem tissue, but there remains a pressing need to define early functional

89 However, there remains a relative paucity of data and some uncert

90 ated control of clade B HIV-1 infection, yet there remains a relative paucity of data regarding the r

91 Despite this, there remains a scarcity of software packages that provi

92 gand interactions to identify new compounds, there remains a shortage of specific databases with prec

93 ial meningitis in children has decreased but there remains a significant burden of disease in adults,

94 ade of experimental and theoretical studies, there remains a significant debate on the nature of over

95 of patients on the transplant waiting list, there remains a significant gap between the need for tra

96 However, there remains a significant lack of generators capable o

97 ation of CNT-enabled products is increasing, there remains a significant lack of information regardin

98 There remains a significant need for development of effe

99 gies for mass spectrometry-based proteomics, there remains a significant need for enhancing the selec

100 combination with a long-acting beta-agonist, there remains a significant subset of patients that requ

101 As a consequence, there remains a significant unmet need in neuro-oncology

102 determinant of RV systolic function in PAH, there remains a significant variability in RV adaptation

103 Yet there remains a steep learning curve in the subsequent c

104 several potent agonists have been described, there remains a strong need for suitable tracers to inte

105 Thus, there remains a strong rationale to suppress AR activity

106 Despite these advances, there remains a substantial need for more high-quality e

107 There remains a substantial proportion of patients older

108 There remains a substantial unmet medical need in hemoph

109 Yet, there remains a surprising lack of tools for GSE testing

110 There remain also needs to understand broader categories

111 ay be goal-irrelevant (incidental features), there remains ambiguity concerning how this is achieved.

112 Despite these limitations, there remains ample opportunity for natural selection to

113 There remains an imperative need for improved surveillan

114 us studies in this area in recent years, but there remains an imperative to demonstrate that the curr

115 As such, there remains an important clinical need to develop ways

116 There remains an intriguing possibility that seizure-ind

117 d differences in case mix between operators, there remains an inverse relationship between PCI operat

118 Furthermore, there remains an unmet demand for an efficient survey of

119 There remains an unmet dermatological need for innovativ

120 Thus, there remains an unmet medical need for more effective a

121 Therefore, there remains an unmet need for a novel therapeutic appr

122 Thus, there remains an unmet need for early diagnostic and pro

123 s in patients with acute coronary syndromes, there remains an unmet need for the development of new t

124 notechnological solutions to biosensing, yet there remains an unmet need in the development of biosen

125 There remains an unmet vaccine need despite decades of r

126 However, there remains an unsettling void in this simple approach

127 Therefore, there remains an urgent and unmet clinical need for the

128 Hence, there remains an urgent need for antidiabetic therapeuti

129 treatment guidelines in the near future, but there remains an urgent need for better diagnostic tests

130 ite significant advancements over the years, there remains an urgent need for low cost diagnostic app

131 There remains an urgent need for rapid diagnostic method

132 Thus, there remains an urgent need of efficacious drugs that c

133 However, there remains an urgent need to develop new vaccines for

134 ) on [O(2)] for these samples, suggests that there remains another class of oxidizing triplet sensiti

135 of AILDs and liver transplantation evolves, there remain areas of unmet needs.

136 Nevertheless, there remained at least seven drugs for which reasonable

137 There remain broad opportunities for the development of

138 However, there remains concern about their efficacy and safety.

139 There remains concern regarding the occurrence of noncom

140 type 1 retinopathy of prematurity (ROP), but there remain concerns about systemic toxicity.

141 covery agitation in children, but even here, there remain concerns about their routine use.

142 sed by critical care organizations; however, there remains confusion about what shared decision makin

143 ered along with reperfusion injury; however, there remains considerable controversy in the literature

144 There remains considerable debate over the active form o

145 promise in preclinical and clinical trials, there remains considerable interest in the development o

146 ommon task in biological investigations, yet there remains considerable room for improvement in align

147 forests respond with increased productivity, there remains considerable uncertainty as to how the lon

148 There remains considerable uncertainty in how anthropoge

149 There remains considerable variability in the distributi

150 d the debate over how many tree species grow there remains contentious.

151 There remains controversy about how best to manage intra

152 ransgenic animal models have been developed, there remains controversy over whether they fully mimic

153 patients with type 2 diabetes mellitus, but there remains controversy regarding an observed associat

154 in the early Drosophila melanogaster embryo, there remains controversy regarding both the extent and

155 There remains controversy regarding several aspects of i

156 There remains controversy regarding the efficacy, safety

157 Despite their success, there remain critical barriers to the more widespread us

158 dergoing percutaneous coronary intervention, there remains debate about differences in efficacy and t

159 However, there remains debate as to whether the association with

160 ments requiring clinical trial coverage, but there remain deficiencies that will need to be addressed

161 lowing discussion among the consensus group, there remained disagreement in 10 cases (kappa = 0.91; 9

162 porting the use of neoadjuvant chemotherapy, there remains disagreement regarding its use vs. selecti

163 There remain evidence-practice gaps in the care provided

164 There remain gaps in knowledge concerning how vascular m

165 However, there remain gaps in our knowledge, primarily regarding

166 iterative process of model development, and there remains great opportunity for advancing our unders

167 However, there remains great variability in the current clinical

168 There remain however several points of contention.

169 There remain, however, many challenges related to the ac

170 There remain, however, some significant challenges to fu

171 There remains, however, a need for methods to propel and

172 There remains, however, a need to examine eDNA persisten

173 There remains, however, a pressing need to elucidate str

174 There remains, however, an unexplained link between hypo

175 There remains, however, the need for an efficient APRM c

176 quality data about these epigenomic domains, there remain important analysis problems that are not ad

177 r to that of adult myasthenia gravis, though there remain important differences regarding presentatio

178 f the breadth of this public health problem, there remain important gaps in scientific knowledge rega

179 changes in ecosystems around the world, but there remain important questions regarding the contexts

180 elopment of tolerance to tumor antigens, but there remains incomplete knowledge about how DC-tolerizi

181 from the market due to severe side effects, there remains interest in some of its many potential med

182 There remain issues such as how to cluster molecular seq

183 ade in terms of molecular therapies for CML, there remain large gaps in our understanding.

184 Yet, there remain limitations regarding load-relaxation of th

185 r, despite numerous theoretical explanations there remains limited empirical evidence for selective m

186 There remains limited insight into the pathophysiology a

187 However, there remains limited surveillance of non-commercial pou

188 Yet, there remains limited understanding of how these cells c

189 However, despite its clinical importance, there remains limited understanding of mechanisms underl

190 However, there remains limited understanding of molecular events

191 lume fluid administration for major surgery, there remains little consensus on optimal strategies, du

192 However, despite attention in model systems, there remains little data on how recombination rate vari

193 T1) can contribute to neuronal excitability, there remains little information on the physiological ro

194 ype of breast cancer with poor survival, but there remains little known about the etiologic factors t

195 ands, were identified over 20 years ago, but there remains little mechanistic evidence to suggest how

196 nitor-like cancer-initiating properties, but there remains little mechanistic insight into this linka

197 There remains little national data evaluating the associ

198 However, there remains little understanding of the function of nu

199 the Expanded Program on Immunization (EPI), there remain major challenges to more effective vaccinat

200 However, at present, there remain many hypotheses on the pulvinar's specific

201 However, despite their apparent success, there remain many open questions about their intrinsic p

202 t has been evaluated in clinical trials, and there remain many opportunities to further investigate k

203 However, there remain many potentially high-impact applications o

204 merous cellular targets have been described, there remain many questions about the mechanism of NSP1

205 ge and advances in prevention and treatment, there remain many questions about this decline.

206 ion referred to as "reverse seroconversion." There remain many uncertain areas that warrant further s

207 There remain many uncertainties regarding this pathway.

208 blast cells is a well-recognized phenomenon, there remains minimal data on differences in MDR activit

209 There remains much room for improvement for the reportin

210 There remains much scientific, clinical, and ethical con

211 f current management of ischemic stroke, but there remains much to be learned about mechanisms of neu

212 g the surfaces of these frameworks, although there remains much to be learned about the origins of th

213 Despite this, there remains much to be learnt about how and when the h

214 fic and public health significance, however, there remains much to be understood about the ecology an

215 Although there remains much to learn about Eph/ephrin signaling i

216 evalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment.

217 There remain no uniform classification criteria that are

218 Overall there remain no validated biomarkers in the youth popula

219 n characterizing and modeling this response, there remains no consensus as to the mechanism that driv

220 herapies have improved patient survival, but there remains no definitive cure.

221 ve mechanisms for the tumor tropism of MSCs, there remains no direct comparison of the efficacy and s

222 is associated with this subset of lymphomas, there remains no evidence for a risk-adapted treatment s

223 eserved ejection fraction (HFpEF) in humans, there remains no evidence-based therapies for HFpEF.

224 establishes a persistent infection for which there remains no feasible cure.

225 leading cause of infant hospitalization and there remains no pediatric vaccine.

226 By the late 20th-early 21st century, there remains no statistically significant relationship

227 hat target proteins for therapeutic benefit, there remains no substitute for the natural properties o

228 eserved ejection fraction (HFpEF) in humans, there remains no therapeutic options for HFpEF.

229 with high rejection rates in MPS1 children, there remains no treatment to prevent blindness or resto

230 n of this syndrome in the late 19th century, there remain numerous unanswered neurobiological questio

231 to what extent they influence the processes there remains only partially understood.

232 There remain open questions in the signaling networks, t

233 espite its widespread use over four decades, there remain open questions regarding its fundamental li

234 There remain opportunities for improvement in medication

235 y for the macromolecular processes occurring there remains poorly characterized.

236 these early years following introduction, so there remains potential for further disease reductions.

237 ictions and total allowable catch (TAC), but there remain problems with compliance and high levels of

238 Nonetheless, there remain psychiatric domains unique to humans.

239 f recurrent cardiovascular events after ACS, there remain questions about how aggressively to reduce

240 Despite the rapid progress in recent years, there remain questions about how diagnostic studies are

241 mber of transplants undertaken in the UK but there remains reluctance to use kidneys from older circu

242 Despite this, there remain remarkably few studies investigating the us

243 double mutant than in either single mutant, there remained residual CD28-dependent responses, defini

244 spectra obtained from cross-linked peptides, there remains room for improvement.

245 Despite this, there remain serious complications from the procedure th

246 There remain serious disparities in access to eye health

247 h in HCV therapeutic development approaches, there remain several key obstacles to the broad implemen

248 There remain several outstanding questions in spatial ec

249 However, there remain significant challenges in the synthesis of

250 been made on materials performance; however, there remain significant concerns about operational and

251 tential in a variety of experimental assays, there remain significant difficulties concerning breadth

252 therapy increased marginally with time, but there remain significant factors associated with differe

253 ical to impede tumor growth and progression, there remain significant gaps in knowledge about the mec

254 Despite these efforts, there remain significant gaps in our knowledge concernin

255 SUMMARY BACKGROUND DATA: There remain significant gaps in our understanding of ac

256 rt of efforts to eliminate malaria, however, there remain significant gaps in our understanding of mo

257 However, there remain significant knowledge gaps about the variat

258 ing advances in the field of nanotechnology, there remain significant research gaps and the opportuni

259 spite this impressive pro-equity trajectory, there remain significant residual inequities in survival

260 roots at harvest may offset the losses, but there remain significant uncertainties about both the si

261 tment for biologically plausible covariates, there remained significant associations of total 25-hydr

262 AN practice parameters was readily apparent, there remained significant variability across all 5 cate

263 insoluble amyloid plaques of hIAPP; however, there remains significant ambiguity in the underlying me

264 ers provide maps of the "spatial gradients," there remains significant confusion because of the lack

265 nder local or general anaesthesia exist, and there remains significant debate within the field regard

266 However, there remains significant patient and geographic variati

267 ensity lipoprotein cholesterol with statins, there remains significant residual risk as evidenced by

268 in the pathology of CNS disorders, however, there remains significant uncertainty about the neuropro

269 Despite this substantial progress, there remains significant work to be accomplished.

270 However, there remains skepticism about the existence of hub dich

271 Still, there remain some cell types rarely encountered and inad

272 Furthermore, there remain some controversies regarding the correlatio

273 hen they are carefully and optimally applied there remain some unresolved statistical issues.

274 While there remains some conflicting evidence, we have assigne

275 Although there remains some controversy, quite a few of these stu

276 itude of preventative and treatment options, there remains some degree of uncertainty in the literatu

277 Presently, there remains some question regarding how selection of c

278 sets of identified palmitoyl-proteins and so there remains some uncertainty over what constitutes the

279 g the obligate liver stage of infection, yet there remains sparse knowledge of specific host regulato

280 However, there remains substantial debate over their design and,

281 However, there remains substantial opportunity to further improve

282 As such, there remains the enticing possibility that glioblastoma

283 Moreover, with any T2 technique, there remains the key issue that there is no physiologic

284 However, there remains the need for alternative insecticidal acti

285 There remains the need, however, for a soluble, versatil

286 However, there remain unanswered questions about the mechanism of

287 There remain unanswered questions surrounding surgical c

288 ons of sensorimotor and cognitive processes, there remains uncertainty about basic aspects of parieta

289 etic variants associated with schizophrenia, there remains uncertainty about the causal genes involve

290 However, there remains uncertainty about whether these thin sheat

291 ctrocatalytic, and sensing applications, yet there remains uncertainty concerning the intrinsic elect

292 recedented opportunities for drug discovery, there remains uncertainty concerning the path to the cli

293 Furthermore, there remains uncertainty regarding the relative importa

294 icator organisms for over a century, however there remains uncertainty with E. coli-based metrics sin

295 e therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between

296 We interpret this result to indicate that there remains unknown but important factor(s) associated

297 ged 9 years and older has been licensed, but there remains urgent medical need for a vaccine that is

298 Nonetheless, there remains urgent need to determine the basis for sep

299 There remains variability in surgical outcomes with or w

300 ss to adequate care than that at present, as there remains variation in survival between European reg